Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Finally, some good news for Novo Nordisk (NYSE: NVO ... (Which is to say, you take a shot once a week.) Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin ...
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.
(Bloomberg) — Novo Nordisk A/S (NVO, NOVO-B.CO) investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw ...
Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback